[Featured Stock] Medytox Rises on Success of Australian Parksin Co.'s COVID-19 Vaccine Phase 1 Trial

[Asia Economy Reporter Minwoo Lee] Medytox's stock price is on the rise. The news of progress in the clinical trial of the novel coronavirus (COVID-19) vaccine jointly conducted with an Australian company appears to have contributed to the strong performance.

As of 10:36 AM on the 30th, Medytox's stock price recorded 181,000 KRW, up 9.9% from the previous day. The positive impact is interpreted as the news of successfully conducting Phase 1 clinical trials of the COVID-19 vaccine in collaboration with the Australian vaccine development company 'Bacsin'.

According to major foreign media including The New York Times on the same day, Medytox and Bacsin conducted Phase 1 clinical trials of the COVID-19 vaccine 'Cobax19' at the Royal Adelaide Hospital in Australia, targeting 40 healthy adults, confirming both safety and tolerability. Accordingly, they plan to proceed with Phase 2 clinical trials as soon as possible.

Previously, Bacsin also confirmed the antiviral effect of Cobax19 against COVID-19 through preclinical animal experiments.

This content was produced with the assistance of AI translation services.